Here is an American study that should be viewed with a negative eye in France because it pleads in favor of the medical use of cannabis. However, in France, therapeutic cannabis is still prohibited.
In the United States it is not. In the case of this study, researchers at Columbia University looked at dronabinol, a synthetic version of cannabis. This is already authorized for many applications, in particular to fight against nausea and vomiting in the context of chemotherapy, for anorexia associated with AIDS or to relieve pain and relax muscles. It is the pain relieving action of dronabinol that has been evaluated by scientists. They wanted to compare the effectiveness of dronabinol to that of the joint in relieving pain.
For this, 30 regular cannabis smokers smoked cannabis and swallowed dronabinol tablets for 2 weeks, blindly, so as not to know what dose of cannabis they were receiving. Some received placebos tablets.
Synthetic cannabis: less addiction
In the end, joint smokers and those who had taken dronabinol were found to be less sensitive to pain than those who had not taken synthetic cannabis. Compared to the joint, dronabinol has been shown to be more effective over time in reducing pain. Taking this treatment also resulted in habituation less compared to the seal.
Not sure that these conclusions convince the French state to legalize therapeutic cannabis. But they could find more echo in other European countries like the Netherlands, Spain, Italy and Germany which have already taken the step of legalization.
>> To read also: Multiple sclerosis: a pain reliever derived from cannabis soon available?
Cannabis is said to worsen mental illness
Hydrangea: the new cannabis?
